BOULDER, Colo., Feb. 20, 2020 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin...
GAINESVILLE, Fla.–(BUSINESS WIRE)–Feb 20, 2020– Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today...
NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announced the publication of results...
NEW YORK, Feb. 20, 2020 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced the completion of patient...
VICTORIA, Feb. 20, 2020 /PRNewswire/ – ImmunoPrecise Antibodies Ltd (the “Company”), a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, announces its commitment to the development of innovative vaccines...
This clinical trial will investigate for the first time a combination of VB-111 with a checkpoint inhibitor. Pathology readouts are expected to shed light on the potential of VB-111 to turn “cold” colorectal tumors “hot.” TEL AVIV, Israel, Feb. 20, 2020 (GLOBE...
Email
Text